Pyxus International is a tobacco company that operates globally.
Pyxus International has reported that its sales and other operating revenues for the fiscal year ending on June 30th, 2022 reached $343.9 million, representing a 3.2% increase from the same period in 2021. However, its net losses increased by 27.8%, amounting to $14.7 million, primarily due to a decrease in tax benefits by $7.6 million. Adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) increased by 17.1% to $17.3 million.
In a statement, Pyxus CEO Pieter Sikkel said, "As expected, our first quarter results were in line with the previous fiscal year. Demand from Asia increased and shipping times have become more normalized, but this was partially offset by longer shipping times from Africa and South America.
As of June 30th, 2022, our inventory has increased by $126 million compared to the previous year. This is primarily due to rising prices and processing costs for new crop green tobacco in South America, as well as the accelerated purchase activity for new crops in certain key markets. Additionally, over 90% our processed tobacco inventory is still allocated to specific customers.
The overall increase in inventory and the processing tobacco inventory levels we committed to have enabled us to meet current demand, and we anticipate strong shipment volumes for subsequent quarters in fiscal year 2023, consistent with historical trends. Despite higher green tobacco prices and processing costs in South America, we have effectively managed working capital to achieve our procurement objectives for the current crop cycle.
Due to unfavorable weather patterns from the La Niña season, crop yields in certain markets in Africa, Asia, and South America have fallen below expectations, exacerbating supply shortages. We are maintaining transparent dialogue with our clients regarding the impact of La Niña and inflation on our business. To address these and other market dynamics, we have accelerated purchasing activities in key markets and continue to invest in research trials, local projects, and additional training for our global agronomy team to further support our efforts to maximize grower efficiency and yields in unpredictable weather patterns.
We continue to anticipate that sales for the fiscal year 2023 will fall between $1.75 billion and $1.95 billion, while adjusted EBITDA will fall between $130 million and $160 million. Looking ahead, we are committed to restoring crop size and ensuring that the quantities in the upcoming years align with customers' expectations as we strive to provide value to stakeholders and work together towards a better world.
This article is compiled from third-party information and is intended for industry professionals to share and learn.
This article does not represent the views of 2FIRSTS and 2FIRSTS cannot confirm the truthfulness and accuracy of the article content. The translation of this article is solely for industry communication and research purposes.
Due to limitations in translation ability, the article may not express the original text accurately. Please refer to the original text for accuracy.
2FIRSTS aligns fully with the Chinese government on any domestic, Hong Kong, Macau, Taiwan, or foreign-related statements or positions.
Copyright of compiled information belongs to the original media and author. If there is any infringement, please contact us for deletion.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
